Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL

Watchlist Manager
Zentalis Pharmaceuticals Inc Logo
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Watchlist
Price: 1.4 USD -3.45% Market Closed
Market Cap: 101m USD

Intrinsic Value

The intrinsic value of one ZNTL stock under the Base Case scenario is 0.73 USD. Compared to the current market price of 1.4 USD, Zentalis Pharmaceuticals Inc is Overvalued by 48%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ZNTL Intrinsic Value
0.73 USD
Overvaluation 48%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Zentalis Pharmaceuticals Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about ZNTL?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ZNTL valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Zentalis Pharmaceuticals Inc.

Explain Valuation
Compare ZNTL to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ZNTL?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Zentalis Pharmaceuticals Inc

Current Assets 288.3m
Cash & Short-Term Investments 280.7m
Other Current Assets 7.6m
Non-Current Assets 38.9m
PP&E 33.1m
Other Non-Current Assets 5.8m
Current Liabilities 37.2m
Accounts Payable 7m
Accrued Liabilities 30.1m
Non-Current Liabilities 37.2m
Other Non-Current Liabilities 37.2m
Efficiency

Free Cash Flow Analysis
Zentalis Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Zentalis Pharmaceuticals Inc

Revenue
26.9m USD
Operating Expenses
-179.6m USD
Operating Income
-152.7m USD
Other Expenses
3.9m USD
Net Income
-148.8m USD
Fundamental Scores

ZNTL Profitability Score
Profitability Due Diligence

Zentalis Pharmaceuticals Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

ROE is Increasing
Low 3Y Average Gross Margin
Low Gross Margin
Negative 3Y Average Net Margin
16/100
Profitability
Score

Zentalis Pharmaceuticals Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

ZNTL Solvency Score
Solvency Due Diligence

Zentalis Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Zentalis Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ZNTL Price Targets Summary
Zentalis Pharmaceuticals Inc

Wall Street analysts forecast ZNTL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZNTL is 5.42 USD with a low forecast of 2.02 USD and a high forecast of 10.5 USD.

Lowest
Price Target
2.02 USD
44% Upside
Average
Price Target
5.42 USD
287% Upside
Highest
Price Target
10.5 USD
650% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Zentalis Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ZNTL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ZNTL Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ZNTL stock?

The intrinsic value of one ZNTL stock under the Base Case scenario is 0.73 USD.

Is ZNTL stock undervalued or overvalued?

Compared to the current market price of 1.4 USD, Zentalis Pharmaceuticals Inc is Overvalued by 48%.

Back to Top